- Home
- Companies
- Debiopharm
- Products
- Pamorelin - Triptorelin - Gonadotropin ...
Pamorelin - Triptorelin - Gonadotropin Releasing Hormone (GnRH)
Triptorelin is a gonadotropin releasing hormone (GnRH) agonist; Triptorelin, the active substance of Decapeptyl/Trelstar/Pamorelin/Triptodur, is a GnRH agonist analogue. An agonist is a chemical that binds to a receptor of a cell and triggers a response by that cell. Triptorelin decreases the serum testosterone to castrate levels (estradiol in females). Androgen deprivation stops the growth of the androgen dependent prostate cancer, alleviating pain and improving thus the quality of life of patients. GnRH agonist treatment achieves similar overall survival rates in advanced prostate cancer as surgical castration.The triptorelin 1-month, 3-month and 6-month sustained release formulations have provided patients with a convenient treatment modality.
- Advanced prostate cancer
- Endometriosis
- In-vitro fertilization programs
- Uterine fibroids
- Precocious puberty
3 dosages:
- 1-month (3.75 mg)
- 3-month (11.2 mg)
- 6-month (22.5 mg)
- Development and registration of the triptorelin 1-, 3- and 6-month sustained release formulations in Europe, in North America and the rest of the world
- Continuous life cycle management (new formulations, route of administration, indications)
- First worldwide registered sustained release formulation of a gonadotropin releasing hormone (GnRH) agonist in 1986.